NAS:TLRY (Canada) Also trade in: Germany Switzerland UK

Tilray Inc

$ 45.17 0.38 (0.85%)
Volume: 178,788 Avg Vol (1m): 1,632,950
Market Cap $: 4.39 Bil Enterprise Value $: 4.49 Bil
P/E (TTM): 0.00 P/B: 11.18
Earnings Power Value 0
Net Current Asset Value -3.11
Tangible Book -1.46
Projected FCF 0
Median P/S Value 102.9
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.75
Cash-To-Debt ranked lower than
96.04% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
TLRY: 0.75
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.05, Med: 0.75, Max: 6.52
Current: 0.75
0.05
6.52
Equity-to-Asset 0.36
Equity-to-Asset ranked lower than
97.21% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
TLRY: 0.36
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.09, Med: 0.34, Max: 0.84
Current: 0.36
-0.09
0.84
Debt-to-Equity 1.13
Debt-to-Equity ranked lower than
100.00% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
TLRY: 1.13
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -10.56, Med: 1.23, Max: 11.35
Current: 1.13
-10.56
11.35
Debt-to-EBITDA -6.04
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
TLRY: -6.04
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -9.07, Med: -7.93, Max: -5.63
Current: -6.04
-9.07
-5.63
Altman Z-Score 3.58
DISTRESS
GREY
SAFE

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -132.55
Operating Margin ranked lower than
80.90% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
TLRY: -132.55
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -133.67, Med: -55.75, Max: -36.51
Current: -132.55
-133.67
-36.51
Net Margin % -159.08
Net Margin ranked lower than
80.42% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
TLRY: -159.08
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -159.08, Med: -62.35, Max: -38.02
Current: -159.08
-159.08
-38.02
ROE % -54.90
ROE ranked lower than
100.00% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
TLRY: -54.9
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -311.83, Med: -191.04, Max: -54.9
Current: -54.9
-311.83
-54.9
ROA % -21.39
ROA ranked lower than
76.81% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
TLRY: -21.39
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -23.82, Med: -19.06, Max: -17.94
Current: -21.39
-23.82
-17.94
ROC (Joel Greenblatt) % -92.85
ROC (Joel Greenblatt) ranked lower than
70.53% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
TLRY: -92.85
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -92.85, Med: -31.08, Max: -23.42
Current: -92.85
-92.85
-23.42

» TLRY's 30-Y Financials

Financials (Next Earnings Date: 2019-08-29)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:TLRY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325411    SIC : 2833
Compare
Traded in other countries 2HQ.Germany 2HQ.Switzerland 0Z6Y.UK
Address 1100 Maughan Road, Nanaimo,, BC, CAN, V9X IJ2

Ratios

Current vs industry vs history
PB Ratio 11.18
PB Ratio ranked lower than
100.00% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
TLRY: 11.18
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 10.91, Med: 36.23, Max: 73.42
Current: 11.18
10.91
73.42
PS Ratio 72.26
PS Ratio ranked lower than
100.00% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
TLRY: 72.26
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 70.43, Med: 164.91, Max: 410.8
Current: 72.26
70.43
410.8
EV-to-EBIT -58.06
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
TLRY: -58.06
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -367.3, Med: -122.65, Max: -55.6
Current: -58.06
-367.3
-55.6
EV-to-EBITDA -62.80
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
TLRY: -62.8
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -399.4, Med: -130.75, Max: -60.1
Current: -62.8
-399.4
-60.1
EV-to-Revenue 76.96
EV-to-Revenue ranked lower than
93.96% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
TLRY: 76.96
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 73.6, Med: 163.95, Max: 419.2
Current: 76.96
73.6
419.2
Current Ratio 2.35
Current Ratio ranked lower than
98.25% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
TLRY: 2.35
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.25, Med: 0.97, Max: 21.37
Current: 2.35
0.25
21.37
Quick Ratio 2.06
Quick Ratio ranked lower than
98.83% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
TLRY: 2.06
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.1, Med: 0.83, Max: 20.75
Current: 2.06
0.1
20.75
Days Inventory 156.50
Days Inventory ranked lower than
85.43% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
TLRY: 156.5
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 149.47, Med: 150.15, Max: 229.57
Current: 156.5
149.47
229.57
Days Sales Outstanding 123.26
Days Sales Outstanding ranked higher than
93.64% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
TLRY: 123.26
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 12.21, Med: 17.47, Max: 139.85
Current: 123.26
12.21
139.85
Days Payable 147.20
Days Payable ranked higher than
86.41% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
TLRY: 147.2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 27.7, Med: 134.7, Max: 221.65
Current: 147.2
27.7
221.65

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.44
Price-to-Median-PS-Value ranked lower than
100.00% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
TLRY: 0.44
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.42, Med: 0.91, Max: 2.4
Current: 0.44
0.42
2.4
Earnings Yield (Joel Greenblatt) % -1.69
Earnings Yield (Greenblatt) ranked lower than
66.90% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
TLRY: -1.69
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1.8, Med: -0.8, Max: -0.3
Current: -1.69
-1.8
-0.3

More Statistics

Revenue (TTM) (Mil) $ 58.36
EPS (TTM) $ -0.85
Beta 0
Volatility % 0
52-Week Range $ 20.1 - 300
Shares Outstanding (Mil) 93.17

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N